82 results about "Myocar dial" patented technology

A method is provided for ablating a portion of the myocardium. The method includes inserting an occlusion catheter into a vessel on a heart, occluding the vessel using the occlusion catheter, inserting an ablation catheter into a chamber of the heart, positioning the ablation catheter against the myocardium, and ablating a portion of the myocardium while the vessel is occluded. The system includes an occlusion catheter having a catheter body including a tubular member having a distal portion and a bend located in the distal portion, a balloon located proximal of the bend and configured to contact an inner surface of the coronary sinus when positioned therewithin, a plurality of marker bands positioned on the catheter body, and a plurality of electrodes positioned on the catheter body.

This application relates to cardiac medical devices, and specifically to adjustable tensioning devices for tissue anchors, to the intraventricular cardiac anchoring or banding devices themselves, to devices and methods for controlling the depth of penetration of tissue anchors, to devices and methods for the joining of both papillary muscles to the mitral valve, to devices and methods for non-invasive “sling” or “loop” tethering of papillary muscles, to devices and methods for establishing suction prior to and during tissue anchor implant, to a double-barreled needle delivery device, and to a method of remodelling the heart muscle by implanting one or more tethers, and then periodically reducing the tether distance over time.

A method for automatically generating a myocardial perfusion map from a sequence of magnetic resonance (MR) images includes determining a region of interest (ROI) in a reference frame selected from a time series of myocardial perfusion MR image slices, registering each image slice in the time series of slices to the reference frame to obtain a series of registered ROIs, and using the series of registered ROIs to segment endo- and epi-cardial boundaries of a myocardium in the ROI.

The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells.

The present invention provides a method for repairing damaged myocardium. The method comprises using a combination of cellular cardiomyoplasty and electrostimulation for myogenic predifferentiation of stem cells and to synchronize the contractions of the transplanted cells with the cardiac cells. The method comprises the steps of obtaining stem or myogenic cells from a donor, culturing and electrostimulating the isolated cells in vitro, and implanting the cells into the damaged myocardium.

A method to determine myocardial wall dynamics and tissue characteristics using a method provided to determine myocardial wall dynamics and tissue characteristics using a 3D model of the myocardium. The method comprises generating an epicardial surface and an endocardial surface from a plurality of SAX and LAX slices; identifying a plurality of nodes on the epicardial and endocardial surfaces or in between these surfaces within the myocardium in a reference frame; defining a set of coefficients, each coefficient being associated with the respective location of the corresponding node in a phase; determining the coefficients and in this way determining the model; determining the myocardial wall dynamics in terms of strain values and displacements.

99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios.

The invention relates to an imaging method and a device for visualizing coronary heart disease, in particular cardiac infarction lesions, in which at least one image of the heart or heart region comprising at least the myocardium is recorded and reproduced using computed tomography part. The method is characterized in that, by windowing the measured data of the image or the data derived therefrom in the region of the myocardium, regions with insufficient blood supply and / or damage are segmented and displayed in the image in a distinctive manner. In particular, the method according to the invention and the associated device can be used to graphically display the extent of damage after a heart attack.

An implantable system is provided that includes: a cell repopulation source comprising genetic material, undifferentiated and / or differentiated contractile cells, or a combination thereof capable of forming new contractile tissue in and / or near an infarct zone of a patient's myocardium; and an electrical stimulation device for electrically stimulating the new contractile tissue in and / or near the infarct zone of the patient's myocardium or otherwise damaged or diseased myocardial tissue.

Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle using a combination of therapies. The method may include the introduction of structurally reinforcing agents. In other embodiments, agents may be introduced into a ventricle to increase compliance of the ventricle. The prevention of remodeling may include the prevention of thinning of the ventricular infarct zone. Another embodiment includes the reversing or prevention of ventricular remodeling with electro-stimulatory therapy. The unloading of the stressed myocardium over time effects reversal of undesirable ventricular remodeling. These therapies may be combined with structurally reinforcing therapies. In other embodiments, the structurally reinforcing component may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.

There is provided a system, method and apparatus for detecting a cardiac event in a subject, including: at least one electrode attached to the subject for obtaining an electrocardiogram of the subject's heart; and means for determining a size of an area under a QRS complex of the electrocardiogram. The at least one electrode may be attached to the subject's skin or to the subject's heart. Preferably, the means for determining the size of the area under the QRS complex of the electrocardiogram is either visual or quantitative. The subject may be a human being or an animal. It is advantageous that the size of the area under the QRS complex of the electrocardiogram is directly proportional to the mass of viable myocardium in the subject's heart. The cardiac event that may be detected may be degenerative cardiomyopathy, acute myocardial infarction, arrhythmia, myocardial ischaemia, or compromised ventricular function.

The invention relates to a method for determining an optimal output of an ablation catheter for a myocardial ablation in a patient with the following steps: creation of at least one at least three-dimensional image recording of an ablation region provided for the myocardial ablation using at least one image recording apparatus; at least partial segmentation of the recorded ablation region to obtain segmentation information using a computation apparatus; at least partial determination from the segmentation information of the location-dependent thickness of the myocardium in the ablation region by the computation apparatus; and determination of the optimal output of the ablation catheter, in particular by the computation apparatus or a separate computation apparatus of an ablation catheter system, as a function of the determined myocardium thickness.

Methods and apparatus for automatically registering an anatomical image with a perfusion image is provided. The method includes acquiring an anatomical image of a heart using a first imaging modality, acquiring a physiological image of the heart using a different second imaging modality, identifying a myocardium of a left ventricle using the physiological image, automatically scoring a plurality of pixels in the anatomical image that are within a predetermined range of the myocardium identified in the physiological image, and registering the anatomical image with the physiological image based on the score.

An MRI apparatus includes an imaging data acquiring unit and a blood flow information generating unit. The imaging data acquiring unit acquires imaging data from an imaging region including myocardium, without using a contrast medium, by applying a spatial selective excitation pulse to a region including at least a part of an ascending aorta for distinguishably displaying inflowing blood flowing into the imaging region. The blood flow information generating unit generates blood flow image data based on the imaging data.

The invention relates to the technical field of a cardioplegic solution, and in particular relates to an autoimmune hemolytic anemia (ALHA) cardioplegic solution and a preparation method thereof. Every 500ml of the ALHA cardioplegic solution contains 552.86-947.76mg of cobamamide, 4.739-5ml of a lidocaine solution of 2% in mass concentration, 30-60mg of pentazocine and 4.1-10ml of a magnesium sulfate solution of 25% in mass concentration. The cardioplegic solution disclosed by the invention can effectively shorten duration of induced cardiac arrest; and the ALHA cardioplegic solution can carry oxygen, so that just few ALHA cardioplegic solution can effectively promote cardiac arrest to avoid hurt of myocardial ischemia reperfusion to cardiac muscle, further improve re-beating success rate in one time and reduce arrhythmia incidence rate after re-beating, and effectively relieve an inflammatory response, so as to effectively protect the cardiac muscle cell.

The invention concerns a data processing apparatus (12) for processing T-wave information (Tl) or ST-segment (ST) information from an electrical signal from a myocardium of a heart of a human or animal, for an assessment of a condition of at least a part of the myocardium or the whole myocardium, characterised in that the data processing apparatus (12) is configured to derive a T-wave deviation value (DV, NDV, 2DV, N2D) from a difference of at least two T-wave parameters (P) or ST-segment parameters (P), wherein each of the two parameters (P) belongs to another T-wave (T) or ST-segment (ST) from the same heart. Further, an assessment apparatus for assessing the condition of at least a part of a myocardium of a heart of an individual human or animal, a method for providing data for an assessment of a condition of at least a part of a myocardium of a heart of a human or an animal, wherein the method includes processing T-wave information from an electrical signal from at least a part ofa myocardium and a diagnosis method for diagnosing a condition or a disease of a heart are proposed. Further, a method for data processing, a method for assessing a condition or a disease of the heartand a diagnosis method are proposed.

A method of determining the amount of intracellular manganese in the myocardium of an individual pre-administered with a manganese contrast agent, or a pharmaceutically acceptable salt thereof, comprising subjecting said individual to a MRI procedure to assess the signal intensity (SI) of images, or more preferably the longitudinal relaxation rate, R1.

The invention discloses an apoptotic body produced by inducing apoptosis of human umbilical cord mesenchymal stem cells in vitro and application thereof for promoting vascular regeneration of rats with myocardial infarction, and belongs to the field of regenerative medicine. At the same time, the invention also relates to a preparation method for obtaining the apoptotic body by inducing apoptosisof human umbilical cord mesenchymal stem cells in vitro. Experiments in vitro of the invention prove that the induction of apoptosis of umbilical cord mesenchymal stem cells can produce the apoptoticbody. At the same time, experiments in vivo prove that when the induced apoptotic body is used in the treatment of rats with myocardial infarction, the recovery of rat heart function and the vascularregeneration of damaged myocardium can be promoted. Therefore, the apoptotic body may become a potential effective agent for improving cardiac function after myocardial infarction.

The present invention relates to a cardio myopeptidin which is isolated from the hearts of non-human healthy mammals. The molecular weight of the cardio myopeptidin is less than 10000 Dalton, the peptide content thereof being 75%˜90%, the free amino acid content 6%˜15%, the ribonucleic acid content less than 2%, and the deoxyribonucleic acid content less than 7.5%. The present invention further provides a method of producing the cardio myopeptidin and the use thereof in producing pharmaceuticals for treating cardiac disorders, specifically the use in producing pharmaceuticals for treating myocardial ischemic and reperfusion injury. The cardio myopeptidin of the present invention can work directly on myocytes, promoting the repair of injuries caused by various reasons, and providing a new way to relieve ischemic and reperfusion injury, and to promote the repair of injured myocardium.

A method to determine myocardial wall dynamics and tissue characteristics using a method provided to determine myocardial wall dynamics and tissue characteristics using a 3D model of the myocardium. The method comprises generating an epicardial surface and an endocardial surface from a plurality of SAX and LAX slices; identifying a plurality of nodes on the epicardial and endocardial surfaces or in between these surfaces within the myocardium in a reference frame; defining a set of coefficients, each coefficient being associated with the respective location of the corresponding node in a phase; determining the coefficients and in this way determining the model; determining the myocardial wall dynamics in terms of strain values and displacements.

A device for monitoring cardiac pacing rate having a measuring unit for receiving an electrical signal representing the patient's cardiac demand, and a computing unit for determining the myocardial energy balance by calculating energy consumed by the myocardium for both an external dynamic work for pumping blood into a vascular system, and an internal static work of the myocardium. Volume and time based measurements are used, and in one embodiment, volumes are estimated and volume ratios are calculated from volume estimates. In another embodiment, volumes are estimated from bioimpedance measurements. A further aspect is a rate adaptive pacemaker, wherein the maximum pacing rate is determined from the myocardial energy balance such that the energy supplied to the myocardium approximately equals the energy consumed by the myocardium for both an external dynamic work for pumping blood into a vascular system and an internal static work of the myocardium.

The invention relates to an injection agent for protecting ischemic myocardium and a preparation method of the injection. Injection emulsion is prepared from the following raw materials in parts by mass: 1 to 5 parts of N-SAHA (Suberoylanilide Hydroxamic Acid), 0.2 to 12.5 parts of emulsifying agent, 2 to 100 parts of oil for injection, 0.02 to 5 parts of solubilizer, 0.03 to 0.4 part of oleic acid, 0.4 to 12.5 parts of glycerinum and the balance of water for injection. The injection emulsion can be effectively used for increasing local drug concentration of the N-SAHA in lipophilic organs such as angiocarpy and / or tissues before cardiac interventional operation, increasing the bioavailability of the N-SAHA, reducing general side effects of the N-SAHA, realizing effective protection on myocardium under an ischemic or reperfusion injury state and reducing or avoiding the occurrence of myocardial infarction; meanwhile, a new optional dosage form is provided for application of the N-SAHAin treating cancer by the injection emulsion.

The present invention provides a preparation method of a three-dimensional construct for regenerating a cardiac muscle tissue comprising; a step of forming a three-dimensional construct by printing and crosslinking the first bioprinting composition comprising a tissue engineering construct forming solution containing decellularized extracellular matrix and a crosslinking agent, and cardiac progenitor cells, and the second bioprinting composition comprising the tissue engineering construct forming solution, mesenchymal stem cells and a vascular endothelial growth factor, to arrange the first bioprint layer and the second bioprint layer alternately; and a step of obtaining a crosslink-gelated three-dimensional construct by thermally gelating the crosslinked three-dimensional construct, and a three-dimensional construct for regenerating a cardiac muscle tissue, and the preparation method according to the present invention not only equally positions the cardiac progenitor cells in the construct but also implements a vascular network composed of vascular cells in the construct, so that the viability of cells can be maintained for a long time and the cell transfer efficiency into the myocardium can be significantly improved.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicament for treating renal toxicity after chemoradiotherapy and cardiovascular and cerebrovascular diseases. The traditional Chinese medicine composition comprises the components, namely rheum officinale, astragalus membranaceus and root of red-rooted salvia. An experiment proves that the traditional Chinese medicine composition effectively treats and relieves renal toxicity caused by tumor radiation and chemotherapy, and simultaneously has an obvious treatment effect on ischemic cardiovascular and cerebrovascular diseases, for example, cerebellar infarction size is reduced, the cerebral ischemic injury is improved, the infarct size of myocardial ischemia reperfusion in rats is reduced, and the content of methylene dioxyamphetamine (MDA) and NOS is reduced.